Evidence map›Paper›PMID 38212531›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

First-in-human study of PSMA-targeting agent, [

Ruiyue Zhao, Miao Ke, Jie Lv, Shaoyu Liu, Yuheng Liu, Jing Zhang, Lifu Xu, Di Gu, Mingzhao Li, Chao Cai and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Radiosynthesis and preclinical evaluation of [Journal of pharmaceutical analysis · 2025
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Ruiyue Zhao *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.ORCID 0000-0001-5242-0785
Miao Ke *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Jie LvDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Shaoyu LiuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Yuheng LiuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Jing ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Lifu XuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Di GuDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Mingzhao LiDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Chao CaiDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Yongda LiuDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Guohua ZengDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
David AlexoffFive Eleven Pharma Inc, 3700 Market St, Philadelphia, PA, 19104, USA.
Karl PloesslFive Eleven Pharma Inc, 3700 Market St, Philadelphia, PA, 19104, USA.
Lin ZhuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China. zhulin111@gmail.com.
Hank F KungFive Eleven Pharma Inc, 3700 Market St, Philadelphia, PA, 19104, USA. kunghf@gmail.com.
Xinlu WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China. 71lu@163.com.
First Affiliated Hospital of Guangzhou Medical University · CNBeijing Normal University · CNUniversity of Pennsylvania · US

Funding

Guangdong regional joint fund 2022A1515110941Guangzhou basic and applied basic research 2023A04J1196Science and technology program of Guangzhou 202201020558
6 · The paper itself

Abstract

purposeThis is a first-in-human study to evaluate the radiation dosimetry of a new prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical, [

methodsThe [

results[

conclusionsWe report herein a streamlined method for high yield synthesis of [

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIProstatic NeoplasmsRadiometryAgedAged, 80 and overFluorine RadioisotopesHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyRadiopharmaceuticalsTissue DistributionAntigens, SurfaceFluorine RadioisotopesFOLH1 protein, humanGlutamate Carboxypeptidase IIRadiopharmaceuticals[18F]AlF-P16-093DiagnosisDosimetryPET/CTProstate cancerPSMA

Identifiers

PMID38212531
OpenAlexW4390765626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.